German startup Formo expects a US Food and Drug Administration no-questions letter for its Formo precision-fermented casein within weeks and is preparing to scale output with co-manufacturers to a few tons per month next year ahead of its US debut.
The company, which develops and pilots production in-house in Frankfurt, is working with a network of contract manufacturing organizations and will scale in line with customer demand, according to cofounder and CEO Raffael Wohlgensinger.
Formo has not ruled out vertically integrated manufacturing later. However, Wohlgensinger said investors would need to see sales in the hundreds of tons to de-risk that step. For now, partnering with co-packers remains attractive commercially given advances the firm says it has achieved in titer, productivity, and yield using its bacterial production host.
“From everything I’ve seen, I think we’re the best in class. We’re approaching what is metabolically possible. We’re maxing out on metrics from yield on glucose and biomass to recovery and ease of recovery in downstream processing.”
He added that moving into larger fermenters and longer production campaigns with CMOs is where the biggest gains will now come.
Formo precision-fermented casein: why use E. coli
While other producers of casein proteins use yeast or filamentous fungi, Formo has selected E. coli for its productivity and efficiency, provided downstream processing can deliver a pure, cost-effective product, Wohlgensinger said.
The company evaluated bacterial, fungal, and yeast systems. Although the lack of secretion can complicate downstream processing and E. coli can carry a negative perception in food, Wohlgensinger said Formo works with a probiotic E. coli strain with demonstrated use to produce more than 100 human-use compounds. He added that the firm has developed a straightforward, cost-efficient downstream process to extract and purify the casein from microbial cells.
The evolving business model
Formo has pivoted from consumer-facing products to a business-to-business ingredients strategy, closing its adjacent koji fermentation operation and branded cheese line to focus on casein proteins.
Instead of competing head-to-head with commodity milk proteins, Formo is positioning alpha-S1 casein as a premium ingredient with competitive cost in use. According to Wohlgensinger, the protein offers superior foaming, emulsification, and oil-holding capacity that can unlock new applications.
The ingredient’s solubility at low pH opens opportunities in clear protein beverages, a space largely led by whey and precision-fermented beta-lactoglobulin where conventional casein typically underperforms, he said.
Formo is also exploring high-protein yogurts and drinkable yogurts, where higher protein loads can lead to grainy textures. Wohlgensinger said the company’s protein can push protein content higher than with regular casein.
He noted that for buyers seeking the lowest-cost or commodity protein, Formo is not the best option today. However, he said the ingredient outperforms plant-based and dairy benchmarks in several applications. In creamers, for example, he said it can surpass sodium phosphate, a common milk-derived additive, which could also support simpler labels.
Unlocking new applications and cleaner labels
Early indications suggest Formo’s single casein protein may be digested more rapidly than conventional casein, which comprises four proteins in a micellar structure. Wohlgensinger cautioned that more research is needed before any claims can be made.
In cheese analogs, Formo’s alpha-S1 casein can deliver stretch and melt while eliminating phosphate salts such as sodium caseinate, potentially simplifying product labels, he said.
Wohlgensinger added that recreating dairy micelles is not always necessary to achieve desired functionality. For the applications Formo and its customers are currently targeting, he said micelles are not required, allowing the company to keep processes simple and reduce cost.
The pitch: high-performance protein
Formo’s casein has self-affirmed GRAS status in the United States. Some large consumer goods companies, however, will wait for an FDA no-questions letter before launching products, according to Wohlgensinger, who expects the letter in the coming weeks.
While no US products containing Formo’s casein are yet on shelves, the company is running sampling and co-development projects with customers ranging from SMEs to multinationals, and is working with RX Food Ingredients to build its pipeline.
Applications drawing interest include ready-to-drink and ready-to-mix protein beverages, yogurts, creamers, coffee products, powders, and protein snacks. Demand is being driven by broader nutrition trends such as weight management, longevity, and the use of GLP-1 drugs.
As a result, Wohlgensinger said the company’s pitch has shifted from animal-free dairy, sustainability, and ethics to performance. He said customers increasingly focus on the business case, a broader narrative shift across the sector.